

Isolation and Identification of Compounds Responsible for Antioxidant Capacity of *Euryale ferox* Seeds

Chang-Wei Song,[†] Shu-Mei Wang,^{†,§} Li-Li Zhou,[‡] Fan-Fan Hou,[‡] Kai-Jin Wang,[#] Quan-Bin Han,[⊥] Ning Li,[#] and Yong-Xian Cheng^{*,†}

[†]State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650204, People's Republic of China

[‡]Division of Nephrology, Nanfang Hospital, Southern Medical University, Key Laboratory for Organ Failure Research, Education Ministry, Guangzhou 510515, People's Republic of China

[§]College of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, People's Republic of China

[#]School of Life Sciences, Anhui University, Anhui 230039, People's Republic of China

[⊥]Institute of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong, People's Republic of China

S Supporting Information

ABSTRACT: *Euryale ferox* seed is consumed medicinally or for food in China. The present study revealed it to contain significant antioxidant activity, which may be associated with its medical applications as a proteinuria inhibitor of diabetic nephropathy. This study resulted in the identification of 3 new sesquiolignans, named euryalins A–C (1–3), and 16 known compounds, which were all first isolated from this plant apart from 5,7,4-trihydroxy-flavanone. The antioxidant potential of the partial isolates was evaluated using the DPPH radical scavenging assay and mesangial cellular assay. Compounds 2, *rel*-(2 α ,3 β)-7-*O*-methylcedrusin (4), syringylglycerol-8-*O*-4-(sinapyl alcohol) ether (5), and (+)-syringaresinol (7) were found to be most active on DPPH assay, whereas compounds 2, 4, 7, (1*R*,2*R*,5*R*,6*S*)-2-(3,4-dimethoxyphenyl)-6-(3,4-dihydroxyphenyl)-3,7-dioxabicyclo[3.3.0]octane, and buddlenol E could significantly inhibit high glucose-stimulated reactive oxygen species production in mesangial cells. The results suggested that *E. ferox* seed could be considered as an excellent source of natural antioxidants and is useful in the prevention of diabetic nephropathy.

KEYWORDS: *Euryale ferox*, Nymphaeaceae, lignans, antioxidant activity

INTRODUCTION

Diabetes mellitus is taking on epidemic proportions around the world because of the rapid change in lifestyle including changed diets and more sedentary work. It is predicted that the patients of diabetes mellitus will double in the period between 2000 and 2030.^{1,2} Diabetes mellitus is an independent risk factor of many diseases such as cardiovascular diseases, stroke, and kidney diseases.^{3,4} Accumulating evidence has demonstrated that diabetes mellitus is the leading cause of diabetic nephropathy, which accounts for nearly half of all new diabetes mellitus patients.² Diabetic nephropathy is a dangerous disease that can finally cause end-stage renal failure. Prevention of the development of diabetic nephropathy has received great attention in recent years. Accumulating research suggests that advanced glycation end product (AGE) formation and AGE-caused oxidative stress play critical roles in the pathogenesis of diabetic nephropathy.^{5–7} Therefore, strategies designed to target oxidative stress may exert therapeutic effects on the progression of diabetic nephropathy.^{7,8}

Due to the capability of antioxidants to attenuate oxidative stress in cells and aid in the prevention and treatment of many human diseases, the search for antioxidants has attracted much attention in the past decades, and many medicinal plants are considered to have great antioxidant potential.⁹ *Euryale ferox*

Salisb. (Nymphaeaceae), an aquatic plant, is the only species of the genus *Euryale* native to eastern Asia and has been found from India to Korea and Japan. In China, *E. ferox* is mainly produced in Guangxi, Shandong, Jiangsu, Hunan, and Anhui provinces.¹⁰ The young stalks and rhizomes of this plant are edible, the seeds, locally known as Qianshi in Chinese as well as cock's head, are consumed medicinally or as food.¹¹ Qianshi is thought to be associated with the channels of the spleen and kidneys. Its main function is to strengthen the spleen and stop chronic diarrhea, to nourish the kidneys, and to stop excessive leucorrhea and prevent premature ejaculation.¹¹ In southern China, the seeds are served as food by adding them to soup or porridge. Notably, recent clinical studies showed Qianshi or preparations containing Qianshi, taking a formula consisting of Qianshi and the fruits of *Rosa laevigata* as an example, are able to reduce proteinuria, a typical syndrome of diabetic nephropathy.^{12–15} However, to date, little is known about the mechanism of the therapeutic effect. Previous papers revealed that the seeds contain tocopherol trimers,¹⁶ cyclic dipeptides,¹⁷ glucosylsterols and cerebrosides.^{16,18} Biological

Received: October 29, 2010

Accepted: December 24, 2010

Revised: December 21, 2010

Published: January 31, 2011

studies indicated that the seed extract showed significant antioxidant activity and cardioprotective property by inducing TRP32 and Trx-1 protein expression and scavenging reactive oxygen species.¹⁹ Most recently, cerebrosides from the seeds were shown to be cytotoxic in the brine shrimp lethality bioassay.¹⁶ Despite studies on the seeds of the plant, there is no study showing a rational correlation between the representative compounds and the therapeutic effects of the seeds for reducing proteinuria. As a follow-up to our group's interest in the intervention of diabetic nephropathy by traditional Chinese medicine,²⁰ in the present study, we hypothesized that the function of the seeds for the treatment of proteinuria of diabetic nephropathy may be mediated by the compounds in the plant with antioxidant activity, because oxidative stress is recognized as a major cause of diabetic nephropathy. A chemical investigation was therefore undertaken, and antioxidant activities of the selected compounds were evaluated by DPPH assay and cellular assay against high glucose-stimulated reactive oxygen species production in mesangial cells.

MATERIALS AND METHODS

General Experimental Procedures. Optical rotations were recorded on a Horiba SEPA-300 polarimeter. UV spectra were determined on a Shimadzu double-beam 210A spectrometer. IR spectra were measured on a Tensor 27 spectrometer with KBr pellets. NMR spectra were collected on a Bruker AV-400 or a DRX-500 spectrometer. EIMS were determined on a Finnigan-4510 spectrometer. ESIMS and HRESIMS were recorded with an API QSTAR Pulsar 1 spectrometer. Column chromatography (CC) was carried out on silica gel (200–300 mesh, Qingdao Marine Chemical Inc., People's Republic of China), RP-18 (40–60 μm , Daiso Co., Japan), MCI gel CHP 20P (75–150 μm , Tokyo, Japan), and Sephadex LH-20 (Amersham Biosciences, Sweden). Semipreparative HPLC was performed on an Agilent 1200 liquid chromatograph; the column used was a 250 mm \times 4.6 mm i.d., 5 μm , Zorbax SB-C₁₈.

Plant Material. The seeds of *E. ferox* produced in Guangxi province were obtained from Yunnan Corp. of Materia Medica (YCM), Kunming, Yunnan Province, People's Republic of China, in May 2009, and were authenticated by Hong-Yan Sun at YCMM. A voucher specimen (CHYX0317) was deposited at the State Key Laboratory of Phytochemistry and Plant Resources in West China of Kunming Institute of Botany.

Extraction and Isolation. The sun-dried and ground seed powders of *E. ferox* (50 kg) were extracted three times with 85% EtOH (90 L \times 3) under reflux. After concentration, the extract (1.2 kg) was suspended in water, which was followed by successive partition with petroleum ether, EtOAc, and *n*-BuOH. The EtOAc-soluble extract (55 g) was applied to a silica gel column chromatography (CC) and eluted with increasing amounts (2%) of MeOH in CHCl₃ and finally MeOH to furnish four fractions (A–D). Fraction C (9.1 g) was divided into three portions (C1–C3) by MCI gel CHP 20P eluted with gradient aqueous MeOH (10%–80%). Fraction C1 (300 mg) was submitted to a Sephadex LH-20 column (CHCl₃/MeOH, 6:4) to yield compounds 11 (3 mg) and 17 (28 mg). Fraction C2 (600 mg) was applied to preparative TLC (CHCl₃/¹PrOH, 30:1) followed by Sephadex LH-20 CC (CHCl₃/MeOH, 6:4) to produce compounds 10 (18 mg), 12 (10 mg), and a mixture containing compounds 8 and 14. This mixture was further purified by semipreparative HPLC (MeOH/H₂O, 60%) to give pure 8 (30 mg), 14 (4 mg). Fraction C3 (115 mg) was fractionated by Sephadex LH-20 CC (MeOH) and purified by preparative TLC (CHCl₃/Me₂CO, 20:1) to give compounds 6 (12 mg) and 7 (6 mg). Fraction D (9.5 g) was submitted to MCI gel CHP 20P column and washed with gradient aqueous MeOH (15–80%) to provide five

Table 1. NMR Data for Compounds 1 and 2 (500 MHz for ¹H and 100 MHz for ¹³C, in CD₃OD)

position	1		2	
	¹³ C	¹ H	¹³ C	¹ H
2	88.6	5.53 d (6.0)	88.6	5.50 d (6.1)
3	55.7	3.47 (m)	55.6	3.42 m
3a	65.0	3.85 overlap, 3.75 overlap	65.0	3.80 overlap, 3.72 overlap
4	117.9	6.70 overlap	117.9	6.69 s
4a	129.5		129.6	
5	137.1		137.0	
5a	32.9	2.60 t (7.5)	32.9	2.60 t (7.4)
5b	35.8	1.80 m	35.8	1.79 m
5c	62.2	3.55 t (6.6)	62.2	3.54 t (6.5)
6	114.1	6.79 br s	114.0	6.79 s
7	145.2		145.2	
7a	147.4		147.5	
1'	139.5		137.2	
2'	103.8	6.70 overlap	111.4	6.96 br s
3'	154.8		151.8	
4'	136.4		148.6	
5'	154.8		116.1	6.65 d (7.6)
6'	103.8	6.70 overlap	119.2	6.85 d (7.6)
1''	131.1		130.7	
2''	114.1	6.72 br s	114.2	6.70 br s
3''	148.7		148.7	
4''	145.8		145.9	
5''	115.9	6.66 d (7.8)	123.0	6.64 d (7.8)
6''	123.1	6.62 d (7.8)	117.4	6.88 d (7.8)
7''	38.1	2.94 dd (15.6, 6.4), 2.89 dd (15.6, 6.4)	37.6	2.90 dd (15.4, 6.2), 2.84 dd (15.4, 6.2)
8''	85.5	4.22 m	83.1	4.39 m
9''	63.5	3.55 overlap, 3.49 overlap	63.8	3.67 dd (15.0, 5.5), 3.62 dd (15.0, 6.5)
7-OMe	56.8	3.86 s	56.8	3.85 s
3'-OMe	56.6	3.75 s	56.6	3.76 s
5'-OMe	56.6	3.75 s		
3''-OMe	56.3	3.77 s	56.6	3.74 s

portions (D1–D5). Fraction D1 (306 mg) was separated by Sephadex LH-20 (MeOH) followed by preparative TLC (CHCl₃/¹PrOH, 25:1) to yield compounds 1 (20 mg), 5 (13 mg), and 16 (4 mg). Fraction D2 (142 mg) was purified by semipreparative HPLC (MeOH/H₂O, 55–70%) to yield compounds 9 (5 mg), 13 (16 mg), and 15 (6 mg). Silica gel CC of fraction D3 (35 mg) eluted with CHCl₃/Me₂CO (25:1) to give 2 (5 mg). Fraction D4 (107 mg) was separated by Sephadex LH-20 CC (MeOH) and successive semipreparative HPLC (MeOH/H₂O, 75%) to yield compounds 3 (2.7 mg), 18 (14 mg), and 19 (5.4 mg). Fraction D5 (75 mg) was fractionated by RP-18 column (MeOH/H₂O, 25–50%) to afford two portions (D5a and D5b). Of these, fraction D5b was purified by silica gel CC (CHCl₃/MeOH, 25:1) to yield compound 4 (8 mg).

Euryalin A (1). 1 was obtained as white solid: $[\alpha]_D^{23} -3.1$ (*c* 0.27, MeOH); IR (KBr) ν_{max} 3427, 2932, 2856, 1723, 1595, 1516, 1502, 1463, 1423, 1327, 1273, 1235, 1214, 1141, 1124, 1034 cm^{-1} ; UV (MeOH) λ_{max} (log ϵ) 281 (3.82), 235 (sh), 205 (4.95); ¹H and ¹³C NMR spectra, see Table 1; electron impact mass spectrometry

Table 2. NMR Data for Compound 3 (500 MHz for ^1H and 100 MHz for ^{13}C , in CD_3OD)

position	^{13}C	^1H	position	^{13}C	^1H
1	136.4		8'	136.4	4.27 m
2	154.5		9'	154.5	3.91 dd (12.0, 5.2), 3.60 overlap
3	104.8	6.71 overlap	1''	104.8	
4	134.7		2''	134.7	6.81 s
5	104.8	6.71 overlap	3''	104.8	
6	154.5		4''	154.5	
7	131.3	6.51 d (15.7)	5''	131.3	6.69 d (8.0)
8	129.9	6.29 dt (15.7, 5.5)	6''	129.9	6.65 d (8.0)
9	63.6	4.18 overlap	7''	63.6	2.96 dd (15.4, 5.6), 2.89 dd (15.4, 5.6)
1'	138.7		8''	138.7	4.18 overlap
2'	105.3	6.71 overlap	9''	105.3	3.54 overlap, 3.48 dd (14.2, 4.2)
3'	154.3		2-OMe	56.5	3.81 s
4'	136.1		6-OMe	56.5	3.81 s
5'	154.3		3'-OMe	56.6	3.79 s
6'	105.3	6.71 overlap	5'-OMe	56.6	3.79 s
7'	74.1	4.92 d (5.4)	3''-OMe	56.3	3.80 s

(EIMS) m/z 570 $[\text{M}]^+$; HR-EIMS m/z 570.2468 $[\text{M}]^+$ (calcd for $\text{C}_{31}\text{H}_{38}\text{O}_{10}$, 570.2465).

Euryalin B (2). 2 was obtained as a white solid: $[\alpha]_{\text{D}}^{23} -2.4$ (c 0.22, MeOH); IR (KBr) ν_{max} 3431, 2925, 2854, 1620, 1513, 1462, 1426, 1271, 1139, 1032 cm^{-1} ; UV (MeOH) λ_{max} ($\log \epsilon$) 282 (3.90), 228 (sh, 4.31), 205 (4.89); ^1H and ^{13}C NMR spectra, see Table 1; electron impact mass spectrometry (EIMS) m/z 540 $[\text{M}]^+$; HR-EIMS m/z 540.2353 $[\text{M}]^+$ (calcd for $\text{C}_{30}\text{H}_{36}\text{O}_9$, 540.2359).

Euryalin C (3). 3 was obtained as a white gum: $[\alpha]_{\text{D}}^{25} -9.3$ (c 0.22, MeOH); IR (KBr) ν_{max} 3442, 2935, 2848, 1590, 1515, 1462, 1421, 1330, 1227, 1125, 1020 cm^{-1} ; UV (MeOH) λ_{max} ($\log \epsilon$) 271 (4.20), 228 (sh), 206 (4.81); ^1H and ^{13}C NMR spectra, see Table 2; electron spray ionization mass spectrometry (ESIMS) (positive-ion mode) m/z 639 $[\text{M} + \text{Na}]^+$; HR-EIMS m/z 616.2504 $[\text{M}]^+$ (calcd for $\text{C}_{32}\text{H}_{40}\text{O}_{12}$, 616.2520).

Biological Activity. DPPH Radical Scavenging Assay. The DPPH assay was carried out as previously described.²¹ L-Ascorbic acid and gallic acid were used as positive controls, and reaction mixtures containing an EtOH solution of 200 μM DPPH (100 μL) and 2-fold serial dilutions of the sample (dissolved in 100 μL of EtOH, with sample concentrations in the range of 2–1000 $\mu\text{g}/\text{mL}$) were placed in a 96-well microplate and incubated at 37 $^{\circ}\text{C}$ for 30 min. After incubation, the absorbance was read at 517 nm by an Emax precision microplate reader, and the mean of three readings was obtained. Scavenging activity was calculated by the following equation:

$$\% \text{ scavenging activity} = 100 \times \frac{\text{absorbance}_{\text{control}} - \text{absorbance}_{\text{sample}}}{\text{absorbance}_{\text{control}}}$$

The SC_{50} value was obtained through extrapolation from linear regression analysis and denoted the concentration of sample required to scavenge 50% of DPPH radicals.

Analysis of Intracellular Reactive Oxygen Species Production. The measurement of intracellular reactive oxygen species production was carried out in rat glomerular mesangial cells (HBZY-1, Life-Science Academy of Wuhan University, Wuhan, China) as previously described.²⁰ To examine the effect of the compounds, mesangial cells were pretreated with the indicated concentration (1 or 10 μM) of the compounds at 37 $^{\circ}\text{C}$ for 1 h and then exposed to either 5.6 mM (normal glucose, NG) or 25 mM (high glucose, HG) D-glucose²² for 3 h using a Neubauer chamber. Fluorescence intensity was determined immediately by a flow cytometer (excitation $\lambda = 488$ nm, emission $\lambda = 515$ nm, BD FACSCalibur system, Franklin Lakes, NJ). The reactive

oxygen species production was expressed as fluorescence intensity relative to control cells incubated in normal glucose and normalized by total cell protein contents for each experimental group of cells.²³

Statistical Analysis. All of the experiments were performed in three replications. Continuous variables, expressed as mean \pm SD, were compared using one-way ANOVA. Pairwise comparisons were evaluated by the Student–Newman–Keuls procedure or Dunnett's T3 procedure when the assumption of equal variances did not hold. The Dunnett procedure was used for comparisons between the reference group and other groups. A two-tailed p value of <0.05 was considered to be statistically significant. Statistical analyses were conducted with SPSS 13.0.

RESULTS AND DISCUSSION

Structure Elucidation of Compounds. Known compounds were identified as *rel*-(2 α ,3 β)-7-*O*-methylcedrusin (4),²⁴ syringylglycerol-8-*O*-4-(sinapyl alcohol) ether (5),²⁵ (1*R*,2*R*,5*R*,6*S*)-2-(3,4-dimethoxyphenyl)-6-(3,4-dihydroxyphenyl)-3,7-dioxabicyclo[3.3.0]octane (6),²⁶ (+)-syringaresinol (7),²⁷ coniferyl aldehyde (8),²⁸ ω -hydroxypropioquiainone (9),²⁹ *trans-p*-hydroxycinnamaldehyde (10),³⁰ *p*-hydroxybenzaldehyde (12),³¹ *p*-hydroxybenzyl alcohol (13),³² 4-hydroxybenzylethyl ether (14),³³ *p*-hydroxyphenethyl alcohol (15),³⁴ pyrogallol acid (16),³⁵ 5,7,4-trihydroxyflavanone (18),¹⁷ and buddlenol E (19)^{36,37} (Figure 1) by comparison of their spectroscopic data to previously reported values. Simple compounds 11 and 17 were each directly identified as 4-ethoxyphenol and 4-ethoxyphenol 2-methoxybenzene-1,3-diol by NMR and MS experiments. To our knowledge, except for 5,7,4-trihydroxyflavanone, all of the other known compounds were isolated from the seeds for the first time.

Compound 1 had the molecular formula $\text{C}_{31}\text{H}_{38}\text{O}_{10}$ deduced from the HR-EIMS. The IR spectrum indicated the presence of hydroxy (3427 cm^{-1}) and aromatic (1595 , 1516 , 1502 , 1463 , 1423 cm^{-1}) groups. The UV spectrum revealed absorptions at 235 and 281 nm. The ^1H NMR spectrum (Table 1) of 1 showed four methoxy groups and two sets of aromatic protons at δ 6.70 (1H, overlap, H-4) and 6.79 (1H, brs, H-6) and at δ 6.72 (1H, brs, H-2''), 6.66 (1H, d, $J = 7.8$, H-5''), and 6.62 (1H, d, $J = 7.8$ Hz, H-6''). Additionally, a signal at δ 6.70 (2H, s, overlap, H-2'




Figure 1. Structures of compounds 1–19.

and H-6') was observed in the ^1H NMR spectrum. The ^{13}C NMR spectrum displayed 18 signals (two overlapped ones), indicative of three aromatic rings in the molecule. The ^1H and ^{13}C NMR (Table 1) signals at δ_{H} 2.94 (1H, dd, $J = 15.6, 6.4$ Hz, Ha-7''), 2.89 (1H, dd, $J = 15.6, 6.4$ Hz, Hb-7''), 4.22 (1H, m, H-8''), and 3.55 (1H, overlap, Ha-9''), 3.49 (1H, overlap, Hb-9'') and δ_{C} 38.1 (C-7''), 85.5 (C-8''), and 63.5 (C-9'') indicated the presence of a 7''-dehydroxyglyceryl residue. The spectroscopic data of **1** were similar to those of acernikol,³⁸ the difference being that one hydroxyl attached at C-7'' of acernikol was missing in **1**. This conclusion was confirmed by ^1H – ^1H COSY cross peaks of H-7''/H-8''/H-9'' and HMBC correlations of H-7'' with C-1'', C-2'', and C-6'' (Figure 2). ROESY correlation between OMe-3'' and H-2'' further confirmed the substituted pattern of the benzene ring. The relative configuration of the dihydrofuran ring in **1** was clarified by ROESY experiments (Figure 2), which showed a correlation between H-2 and H-3, revealing a *cis*-relationship of these two protons. The absolute configuration at C-8'' remained undetermined. Therefore, compound **1** was defined as 7''-dehydroxyacernikol and named euryalin A.

Compound **2** was assigned the molecular formula $\text{C}_{30}\text{H}_{36}\text{O}_9$ from its HR-EIMS. The IR spectrum showed absorption bands at 3431, 1662, and 1426 cm^{-1} , indicative of hydroxy and aromatic moieties. The UV spectrum indicated absorptions at 228 (sh) and 282 nm. The IR, UV, and ^1H and ^{13}C NMR spectroscopic data of **2** resembled with those of **1**. The only difference was that OMe-5' in **1** was absent in **2**, which resulted in an ABX coupling

pattern in **2** [δ_{H} 6.96 (1H, br s, H-2'), δ_{H} 6.65 (1H, d, $J = 7.6$ Hz, H-5'), and δ_{H} 6.85 (1H, brd, $J = 7.6$ Hz, H-6')]. Analysis of ^1H – ^1H COSY, HMQC, HMBC, and ROESY experiments confirmed the planar structure and allowed unambiguous assignments of NMR data for compound **2**. The relative configuration at the dihydrofuran ring was determined by the ROESY experiments. The ROESY correlation between H-2 and H-3 revealed a *cis*-type isomer. The absolute configuration at C-8'' remained unknown. The above evidence allowed compound **2** to be determined as 7''-dehydroxy-5'-demethoxyacernikol and named euryalin B.

Compound **3** exhibited a $[\text{M}]^+$ ion peak at m/z 616.2504 in the HR-EIMS, in accordance with the molecular formula $\text{C}_{32}\text{H}_{40}\text{O}_{12}$. The IR absorptions at 3442, 1590, 1515, 1462, and 1421 cm^{-1} indicated the presence of hydroxy and aromatic moieties. The ^{13}C NMR spectrum showed 18 aromatic carbons (4 overlapped ones) corresponding to three benzene rings. The similarity of the NMR data of **3** to those of **5** indicated that they are analogues, except for the addition of a 7-dehydroxyguaiacylglyceryl moiety in the molecule of **3** [δ_{H} 2.96 (1H, dd, $J = 15.4, 5.6$ Hz, Ha-7''), 2.89 (1H, dd, $J = 15.4, 5.6$ Hz, Hb-7''), 4.18 (1H, overlap, H-8''), 3.54 (1H, overlap, Ha-9''), 3.48 (1H, dd, $J = 14.2, 4.2$ Hz, Hb-9''), δ_{C} 38.0 (C-7''), 85.6 (C-8''), 63.4 (C-9'')]. The HMBC correlation between H-8'' and C-4' and consideration of their chemical shifts suggested the connection of C-4' and C-8'' via an ether linkage. The coupling constant between H-7' and H-8' is 5.4 Hz, indicative of an *erythro* isomer.^{26,39} So far, the




Figure 2. Key HMBC and ROESY correlations for compound 1.


Table 3. DPPH Radical Scavenging Activity^a of the Extracts, Fractions,^b and Isolates

sample	DPPH (SC ₅₀)	sample	DPPH (SC ₅₀)
EtOH extracts	68.7	9	103.1
petroleum ether fraction	29.0	10	2085.3
EtOAc fraction	20.4	11	768.7
<i>n</i> -BuOH fraction	78.8	12	495.2
1	237.2	13	1317.7
2	6.8	14	699.1
3	162.3	15	830.4
4	10.4	16	26.2
5	10.2	17	41.1
6	27.5	18	209.7
7	12.9	ascorbic acid	20.8
8	477.5	gallic acid	10.7

^a SC₅₀ values of the extracts and fractions, and the isolates are represented as $\mu\text{g}/\text{mL}$ and μM , respectively. ^b 5 g of powdered *E. ferox* seeds was exhaustively extracted by 95% EtOH (10 mL \times 3) under reflux followed by evaporation to yield EtOH extracts; partition of EtOH extracts suspension in water by petroleum ether, EtOAc, and *n*-BuOH afforded respective fraction for DPPH assay.

absolute configuration at C-8' has not been determined. Consequently, compound 3 was identified as 4'-O-(2-guaiacyl-2,3-propanediol)syringylglycerol-8-O-4-(sinapyl alcohol) ether and given the name euryalin C.

Antioxidant Activity Evaluation of Compounds. Because *E. ferox* seeds are always used to treat kidney diseases including diabetic nephropathy and oxidative stress has been considered to be one cause of diabetic nephropathy, we evaluated the antioxidant property of the isolated compounds of *E. ferox* seeds. Although many methods have been developed to measure the antioxidant activity, the DPPH radical scavenging assay has been considered to be the most reliable one and is used widely.⁹ Therefore, the antioxidant capability of the extracts, fractions, and isolated compounds of the *E. ferox* seeds were first examined by DPPH assay using ascorbic acid and gallic acid as positive controls. As shown in Table 3, the EtOAc fraction displayed the most potent activity (SC₅₀ = 20.4 μM). Compounds 2, 4, 5, and 7 exhibited strong effects against DPPH assay with SC₅₀ values of 6.8, 10.4, 10.2, and 12.9 μM , respectively, comparable to that of the positive control (gallic acid or ascorbic acid). Interestingly,



ANOVA, $p < 0.01$; * $p < 0.05$ vs NG, # $p < 0.05$ vs HG

Figure 3. Lignan compounds inhibited high glucose-induced ROS production in mesangial cells. Data are expressed as mean \pm SD of three independent experiments. ANOVA, $p < 0.001$; *, $p < 0.05$ versus NG; #, $p < 0.05$ versus HG.

although the structures of compounds 1 and 2 are similar, except that compound 1 contains an additional methoxy group, the antioxidant activities of compounds 1 and 2 are very different. These data suggested that the presence of OMe-5' might decrease the inhibitory activity. To further evaluate the antioxidant capacity of lignans (i.e., compounds 1–6 and 19), mesangial cells were treated with lignans before stimulation by high glucose. As shown in Figure 3, high glucose-stimulated reactive oxygen species production was significantly inhibited by compounds 2, 4, 6, 7, and 19 at the concentrations of 10 μM . The above results indicated that the diverse components in the seeds with antioxidants activity and their synergistic antioxidant effects may be important reasons for the therapeutic effect of the seeds to reduce proteinuria, and *E. ferox* seeds would be good candidates in the search for natural antioxidants useful for the prevention of diabetic nephropathy.

ASSOCIATED CONTENT

Supporting Information. ¹H and ¹³C NMR spectra of compounds 1–3, HMBC and ROESY correlations of compounds 1 and 2, references to known compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*Phone/fax: +86-871-5223048. E-mail: yxcheng@mail.kib.ac.cn.

Funding Sources

This work was financially supported by a Key Project for Drug Innovation (2008ZX09401-004) from the Ministry of Science; Technology of China and "Talent Scholarship for the Youth of Yunnan" (No. 2007PY01-48); and The Open Research Fund of State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources.

REFERENCES

(1) Wild, S.; Sicree, R.; Roglic, G.; King, H.; Green, A. Global prevalence of diabetes, estimates for the year 2000 and projections for 2030. *Diabetes Care* **2004**, *27*, 1047–1053.

- (2) Ha, H.; Hwang, I. A.; Park, J. H.; Lee, H. B. Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. *Diabetes Res. Clin. Pract.* **2008**, *82s*, s42–s45.
- (3) Alzaid, A. A. Microalbuminuria in patients with NIDDM. An overview. *Diabetes Care* **1996**, *19*, 79–89.
- (4) Bhatia, S.; Shukla, R.; Madhu, S. V.; Gambhir, J. K.; Prabhu, K. M. Antioxidant status, lipid peroxidation and nitric oxide end products in patients of type 2 diabetes mellitus with nephropathy. *Clin. Biochem.* **2003**, *36*, 557–562.
- (5) Ha, H.; Kim, K. H. Role of oxidative stress in the development of diabetic nephropathy. *Kidney Int.* **1995**, *48* (Suppl. 51), s18–s21.
- (6) Lehmann, R.; Schleicher, E. D. Molecular mechanisms of diabetic nephropathy. *Clin. Chim. Acta* **2000**, *297*, 135–144.
- (7) Adeline, L. Y.; Tan, B. B.; Josephine, M. F.; Mark, E. C. AGE, RAGE, and ROS in diabetic nephropathy. *Diabetic Nephropathy* **2007**, *27*, 130–143.
- (8) Jagtap, A. G.; Patil, P. B. Antihyperglycemic activity and inhibition of advanced glycation end product formation by *Cuminum cyminum* in streptozotocin induced diabetic rats. *Food Chem. Toxicol.* **2010**, *48*, 2030–2036.
- (9) Krishnaiah, D.; Sarbaty, R.; Nithyanandam, R. A review of the antioxidant potential of medicinal plant species. *Food Bioprod. Process.* **2010**, doi: 10.1016/j.fbp.2010.04.008.
- (10) Li, L. J.; Wu, Y. F.; Cao, B. S. Research progress of *Euryale ferox* seeds. *China Vegetable* **2007**, 81–88.
- (11) Simmons, F. J. Edible nuts, nut-like fruits and seeds. In *Food in China: A Cultural and Historical Inquiry*; CRC Press: Boca Raton, FL, 1991; pp 285–286.
- (12) Song, J.; Wu, Q. N. Analysis of therapeutic effects of Qianshi on proteinuria. *Chin. J. Mod. Drug Appl.* **2009**, *3*, 133–134.
- (13) Guo, R. A.; Tang, X. H.; Sun, D. J.; Li, Z. F.; Liu, C. Y. Case study of thirty-seven patients with proteinuria treated by Qianshi. *J. Shangdong Coll. Tradit. Chin. Med.* **1993**, *17* (1), 32–33.
- (14) Zhang, R.; Cui, Z. M. Advance of *Euryale ferox* Salisb. fundamental and application research. *Chin. Sci. Technol. Inf.* **2009**, *26* (130–131), 153.
- (15) Peng, D. P. New breakthrough of uremia therapy by traditional Chinese medicine. *Chin. Sci. Technol. Inf.* **2005**, *12*, 173.
- (16) Row, L. C.; Ho, J. C.; Chen, C. M. Cerebrosides and tocopherol trimers from the seeds of *Euryale ferox*. *J. Nat. Prod.* **2007**, *70*, 1214–1217.
- (17) Li, M. H.; Yang, X. Q.; Wan, Z. J.; Yang, Y. B.; Li, F.; Ding, Z. T. Chemical constituents of the seeds of *Euryale ferox*. *Chin. J. Nat. Med.* **2007**, *5*, 24–26.
- (18) Zhao, H. R.; Zhao, S. X.; Sun, C. Q.; Guillaume, D. Glucosylsterols in extracts of *Euryale ferox* identified by high resolution NMR and mass spectrometry. *J. Lipid Res.* **1989**, *30*, 1634–1637.
- (19) Das, S.; Der, P.; Raychaudhuri, U.; Maulik, N.; Das, D. K. The effect of *Euryale ferox* (Makhana), an herb of aquatic origin, on myocardial ischemic reperfusion injury. *Mol. Cell. Biochem.* **2006**, *289*, 55–63.
- (20) Tong, X. G.; Zhou, L. L.; Wang, Y. H.; Xia, C. F.; Wang, Y.; Liang, M.; Hou, F. F.; Cheng, Y. X. Acortatarins A and B, two novel antioxidative spiroalkaoids with a naturally unusual morpholine motif from *Acorus tatarinowii*. *Org. Lett.* **2010**, *12*, 1844–1847.
- (21) Yoshida, T.; Mori, K.; Hatano, T.; Okumura, T.; Uehara, I.; Komagoe, K.; Fujita, Y.; Okuda, T. Studies on inhibition mechanism of autoxidation by tannins and flavonoids. V. Radical-scavenging effects of tannins and related polyphenols on 1,1-diphenyl-2-picrylhydrazyl radical. *Chem. Pharm. Bull.* **1989**, *37*, 1919–1921.
- (22) Xia, L.; Wang, H.; Munk, S.; Frecker, H.; Goldberg, H. J.; Fantus, I. G.; Whiteside, C. I. Reactive oxygen species, PKC- β 1, and PKC- ζ mediate high-glucose-induced vascular endothelial growth factor expression in mesangial cells. *Am. J. Physiol. Endocrinol. Metab.* **2007**, *293*, E1280–E1288.
- (23) Rygiel, T. P.; Mertens, A. E.; Strumane, K.; Kammen, R.; Collard, J. G. The Rac activator Tiam1 prevents keratinocyte apoptosis by controlling ROS-mediated ERK phosphorylation. *J. Cell Sci.* **2008**, *121*, 1183–1192.
- (24) Refer to Supporting Information.
- (25) Refer to Supporting Information.
- (26) Refer to Supporting Information.
- (27) Refer to Supporting Information.
- (28) Refer to Supporting Information.
- (29) Refer to Supporting Information.
- (30) Refer to Supporting Information.
- (31) Refer to Supporting Information.
- (32) Refer to Supporting Information.
- (33) Refer to Supporting Information.
- (34) Refer to Supporting Information.
- (35) Refer to Supporting Information.
- (36) Refer to Supporting Information.
- (37) Refer to Supporting Information.
- (38) Morikawa, T.; Tao, J.; Ueda, K.; Matsuda, H.; Yoshikawa, M. Medicinal foodstuffs. XXXI. Structures of new aromatic constituents and inhibitors of degranulation in RBL-2H3 cells from a Japanese folk medicine, the stem bark of *Acer nikoense*. *Chem. Pharm. Bull.* **2003**, *51*, 62–67.
- (39) Kuima, K.; Otsuka, H.; Ide, T.; Ogimi, C.; Hirata, E.; Takushi, A.; Takeda, Y. Sesquiterpene glycosides and sesquilignan glycosides from stems of *Alangium premnifolium*. *Phytochemistry* **1998**, *48*, 669–676.